OPKO Health

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OPKO Health reports robust Q4 performance and outlines growth strategies

OPKO Health's Q4 2022 earnings call highlighted positive performance, innovative strengths, challenges in market positioning, and opportunities for growth and profitability.
The company's focus on product development, operational efficiencies, and strategic clarity underscores a commitment to driving shareholder value and market leadership.
Analyst inquiries and management responses showcased transparency, strategic foresight, and a proactive approach to addressing market dynamics and regulatory challenges.

OPKO Health reports Q1 revenue growth, strategic partnerships with Merck

OPKO Health's Q1 2023 performance reflects revenue growth in Pharmaceuticals but challenges in Diagnostics segment revenue.
Strengths lie in strategic partnerships with Merck, diversified growth initiatives, and cost-saving measures.
Challenges include limited disclosure on NGENLA approval and revenue recognition complexities.
Opportunities exist in new revenue streams, specialty testing expansion, and strategic collaborations for future growth.
Overall, OPKO Health's performance showcases a mix of strengths, challenges, and opportunities for strategic growth and market leadership.

OPKO Health reports improved Q2 performance and growth opportunities

OPKO Health's Q2 2023 performance showed improvements in operating income and revenue despite challenges in the Diagnostics segment.
The company's strategic strengths lie in successful product approvals, collaborations with Merck, and revenue diversification efforts.
While facing challenges such as revenue fluctuations and profitability concerns, OPKO Health is poised for growth with promising opportunities ahead.
Overall, OPKO Health's financial outlook remains positive, with a focus on profitability and expansion through strategic initiatives and partnerships.

OPKO Health excels in Q3 with revenue growth and innovation

OPKO Health's Q3 2023 performance showcased revenue growth, strong product offerings, and strategic advancements in healthcare solutions.
The company's strengths include successful products, cost-cutting measures, and a focus on innovation through collaborations and contracts.
Challenges include the need for more detailed financial disclosures and transparent communication on operational metrics.
Amidst challenges, opportunities for growth through product expansion, partnerships, and operational optimization are key focus areas for OPKO Health.

OPKO Health excels in 2023 with strategic partnerships and growth

OPKO Health demonstrated strong performance in 2023 with key achievements and positive growth in sales and collaborations.
While facing challenges such as revenue decline in the Diagnostics segment, the company is actively addressing them through cost reduction efforts.
Strategic partnerships, financial refinancing, and clear guidance for 2024 position OPKO Health for continued success and growth.

OPKO Health sells assets, expands therapies globally for growth

OPKO Health is strategically streamlining operations and expanding globally.
Despite revenue declines, the company is focused on profitability and growth.
Strong progress in ModeX programs and collaborations for new therapies.
Emphasis on oncology testing and potential partnerships in oncology space.

OPKO Health reports robust Q2 performance and eyes growth opportunities

OPKO Health's Q2 2024 earnings call highlighted strong financial performance, strategic initiatives for growth, and a focus on operational efficiency and innovation.
The company faces challenges in managing expectations, addressing concerns, and navigating potential acquisitions, but opportunities in collaborations and market expansion are promising.
Overall, OPKO Health's disciplined approach to financial management, clinical development, and strategic partnerships positions it for continued success and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia on Thursday, November 2, 2023. These data will be presented in a poster, “Control of Secondary Hyperparathyroidism with Extended-release Calcifediol is Associated with Slower CKD Progression” (#TH-PO1152) at 10:00 a.m. Eastern time in Exhibit Halls B-D by authors Charles W. Bishop Ph.D., Stephen A. Strugnell Ph.D. and Akhtar Ashfaq, M.D., FACP, FASN.

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

OPK and PFE received FDA approval for Ngenla in June. This enables OPK to receive royalties going forward. OPK has continued to lose money due to its lab business. The business had sales fall off following the decline in COVID testing. OPK needs to right size the business.

OPKO Health: FDA Approval To Save The Company

OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease threats.

OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats

Provides Initial $59 Million and up to $168 Million Contingent on Milestones Provides Initial $59 Million and up to $168 Million Contingent on Milestones

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

OPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presentations of long-acting peptides.

OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations

OPKO Health's (OPK) potential in RAYALDEE raises optimism about the stock.

Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances.

OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates

OPKO Health, Inc. (NASDAQ:OPK ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Phillip Frost - Chairman & Chief Executive Officer Elias Zerhouni - President & Vice Chairman Adam Logal - Senior Vice President & Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Yi Chen - H.C. Wainwright & Co. Michael Petusky - Barrington Research Yale Jen - Laidlaw & Company Operator Good day, and welcome to the OPKO Health Second Quarter 2023 Financial Results Conference Call.

OPKO Health, Inc. (OPK) Q2 2023 Earnings Call Transcript

OPKO Health (OPK) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.04 per share a year ago.

OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates

OPKO Health stock has bounced back since February but remains down over 11% since last year. OPK stock's rally in recent months has been supported by strong buying volume and positive earnings revisions. The company's collaboration with Merck and potential milestone payments contribute to its growth potential.

OPKO Health: Improving Profitability Should Drive Shares Forward Post Q2 Earnings

MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 3, 2023. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on August 3rd beginning at 4:30 p.m. Eastern time.

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

Neogen

Procore Technologies

NEOG, OPK and PCOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 19, 2023.

Best Momentum Stocks to Buy for July 19th

Diversified healthcare company OPKO Health Inc. NASDAQ: OPK shares may be low priced, but its businesses pipeline of treatments and upside potential may deserve a higher valuation. Shares trade at 1.6X sales.

OPKO Health is the Little Giant of Diversified Healthcare

Opko will share profits on the drug's sales with Pfizer. Ngenla is a treatment for pediatric growth hormone deficiency.

Why Shares of Opko Health Jumped on Thursday

The latest approval for OPKO Health's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.

OPKO Health's (OPK) NGENLA Approved by FDA for GHD Treatment

Pfizer

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. NGENLA is expected to become available for U.S. prescribing in August 2023. Growth hormone deficiency (.

FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

Why Is OPKO Health (OPK) Down 17.2% Since Last Earnings Report?

Merck

In the first three months of 2023, the company posted $237.6 million in revenue, up 28.2% from the previous quarter. In addition to the Merck deal, OPKO received a $7 million payment from Vifor in Q1 2023, thanks to the German price approval for Rayaldee.

OPKO Health's Future After Merck Deal: Bright Or Uncertain

Aditxt Inc

Clover Health Investments

Novo Integrated Sciences, Inc.

Senseonics Holdings

Spectrum Pharma

Tuya

Penny stocks to buy for under $1 but are they worth the risk? The post 7 Hot Penny Stocks Under $1.10 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks Under $1.10 To Watch This Week

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall first-quarter results reflect soft performances.

OPKO Health (OPK) Q1 Earnings and Revenues Top Estimates

OPKO Health, Inc. (NASDAQ:OPK ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Phillip Frost - Chairman & CEO Elias Zerhouni - President & Vice Chairman Adam Logal - SVP, CFO, CAO & Treasurer Steven Rubin - EVP, Administration & Director Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Maurice Raycroft - Jefferies Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright & Co. Operator Good afternoon, and welcome to the OPKO Health First Quarter 2023 Financial Results Conference Call.

OPKO Health, Inc. (OPK) Q1 2023 Earnings Call Transcript

OPKO Health (OPK) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.08 per share a year ago.

OPKO Health (OPK) Reports Q1 Loss, Tops Revenue Estimates

MIAMI, May 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023. First quarter business highlights include the following: OPKO Health's ModeX Therapeutics, Inc. (ModeX) entered into an exclusive worldwide license and collaboration agreement with Merck to develop MDX-2201 for Epstein-Barr virus.

OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results

American Assets

AbbVie

Byline Bancorp

Coastal Financial Corp

Clear Channel Outdoor Holdings

Compass Minerals

Enovix Corporation

Heartland Express

iHeartMedia

JELD-WEN Hld

Mineralys Therapeutics Inc

PacWest Bancorp

Precigen

Paramount Group

Purple Innovation

B. Riley Financial

Cassava Sciences Inc

Summit Therapeutics

SPDR S&P 500 ETF Trust

Triumph Financial Inc

LendingTree

Vera Therapeutics

Strong Small-Cap Insider Buys: Q1 2023

MIAMI, April 25, 2023 (GLOBE NEWSWIRE) --  OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2023 after the close of the U.S. financial markets on Wednesday, May 3, 2023. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 3rd beginning at 4:30 p.m. Eastern time.

News for OPKO Health Stock (OPK)